High Growth Tech Stocks in Europe for May 2025

As European markets experience a boost in sentiment following a de-escalation in the U.S.-China trade tensions, with the STOXX Europe 600 Index rising by 2.10%, investors are keenly observing how these developments might influence high-growth sectors, particularly technology. In such an environment, identifying promising tech stocks involves looking for companies that not only demonstrate robust innovation and adaptability but also have the potential to capitalize on improved trade relations and economic conditions.

Top 10 High Growth Tech Companies In Europe

Name	Revenue Growth	Earnings Growth	Growth Rating
KebNi	21.51%	66.96%	★★★★★★
Archos	21.07%	36.58%	★★★★★★
Yubico	20.18%	30.36%	★★★★★★
Pharma Mar	25.21%	43.09%	★★★★★★
Elicera Therapeutics	75.80%	107.14%	★★★★★★
Skolon	31.51%	99.52%	★★★★★★
CD Projekt	33.48%	37.39%	★★★★★★
XTPL	86.66%	143.68%	★★★★★★
Xbrane Biopharma	24.95%	56.77%	★★★★★★
Elliptic Laboratories	36.34%	79.05%	★★★★★★

Click here to see the full list of 227 stocks from our European High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Lectra (ENXTPA:LSS)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Lectra SA offers industrial intelligence solutions across the fashion, automotive, and furniture markets globally, with a market cap of €896.79 million.

Operations: The company generates revenue from the Americas (€176.26 million), Asia-Pacific (€134.84 million), and EMEA regions (€220.46 million). It provides industrial intelligence solutions to fashion, automotive, and furniture markets worldwide.

Lectra is making significant strides in the global fashion industry with its Valia Fashion platform, now expanding into new markets like Mexico and Brazil. This move underscores its commitment to Industry 4.0, enhancing production efficiency through automation and real-time data integration. With a revenue growth forecast of 5.9% annually, outpacing the French market's 5.1%, and an impressive annual earnings growth projection of 20.8%, Lectra is poised for robust expansion. Moreover, the company's recent M&A activities signal strategic positioning for future scalability in a highly competitive sector.

• Navigate through the intricacies of Lectra with our comprehensive health report here.

• Explore historical data to track Lectra's performance over time in our Past section.

Cint Group (OM:CINT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Cint Group AB (publ) offers software solutions for digital insights and research technology on a global scale, with a market capitalization of SEK2.58 billion.

Operations: Cint Group AB focuses on digital insights and research technology, generating revenue primarily from Cint Exchange (€115.57 million) and Media Measurement (€50.13 million).

Cint Group, navigating through a transformative phase, is poised for significant growth with an anticipated revenue increase of 4.5% annually, outpacing Sweden's average of 4.1%. Despite current unprofitability, the company's earnings are expected to surge by nearly 100% per year over the next three years. Recent strategic board changes and a successful private placement raising SEK 2.88 million underscore its proactive approach in strengthening governance and financial footing. These moves, coupled with a sharp reduction in net loss from EUR 7.81 million to EUR 1.83 million year-over-year, signal robust potential for turning profitability around amidst volatile market conditions.

• Unlock comprehensive insights into our analysis of Cint Group stock in this health report.

• Learn about Cint Group's historical performance.

Synektik Spólka Akcyjna (WSE:SNT)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Synektik Spólka Akcyjna offers a range of products, services, and IT solutions for surgery, diagnostic imaging, and nuclear medicine in Poland with a market capitalization of PLN1.90 billion.

Operations: Synektik focuses on providing specialized solutions in surgery, diagnostic imaging, and nuclear medicine within Poland. The company generates revenue through the sale of medical products and services tailored to these fields.

With a robust 22.1% increase in earnings over the past year, Synektik Spólka Akcyjna outstrips its sector's average, showcasing its capacity to generate profit more efficiently than many peers in the Healthcare Services industry. The company's commitment to innovation is evident from its R&D investments, aligning with an 8.7% forecasted annual revenue growth which surpasses the Polish market prediction of 4.7%. Furthermore, an impressive projected annual earnings growth rate of 15.6% positions Synektik well for future expansions. This financial vigor is complemented by a strategic operational focus that promises sustained competitive advantage and potentially lucrative returns for stakeholders involved in this dynamic sector.

• Click to explore a detailed breakdown of our findings in Synektik Spólka Akcyjna's health report.

• Gain insights into Synektik Spólka Akcyjna's historical performance by reviewing our past performance report.

Turning Ideas Into Actions

• Delve into our full catalog of 227 European High Growth Tech and AI Stocks here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com